DRG Market Assessment reports

Since 2018, the U.S. treatment landscape for migraine prophylaxis has undergone a major expansion with the entry of the novel calcitonin gene-related peptide (CGRP)-targeting monoclonal antibodies…

With only a small percentage of patients harboring a biomarker-driven metastatic squamous non-small-cell lung cancer (NSCLC) (about 10% of all patients in the G7 countries), the preferred first-…

Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…

Cystic fibrosis (CF) is a genetic disease caused by any one of the more than 2,000 mutations identified in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Such mutations lead…

Clarivate Epidemiology’s coverage of the human papillomavirus (HPV) vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…

The treatment landscape for advanced HR-positive / HER2-negative breast cancer is continually evolving. CDK4/6 inhibitors, such as Pfizer’s Ibrance and Novartis’s Kisqali, are commonly used in…

TNF-alpha inhibitors remain the primary choice for psoriatic arthritis (PsA) after conventional DMARD failure, howeverbut competing biologics such as IL-17 inhibitors (Cosentyx, Taltz, Bimzelx), IL…

Immune checkpoint inhibitors continue to dominate the treatment of non-small-cell lung cancer (NSCLC), while biomarker-based approaches are driving increasing patient segmentation. 2023 saw the…

The demand for safe and effective obesity drugs is increasing due to the rising prevalence of obesity and the growing interest in incretin therapies, whose efficacy is approaching that of bariatric…

Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin. It typically develops in early childhood and can persist into adulthood. The…

Migraine is a major public health concern in China, where it affects approximately 65 million people, making it the world’s largest migraine population. The disease is a heterogeneous condition…